Covidien's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Covidien (COV)

Q2 2012 Earnings Call

April 27, 2012 8:30 am ET

Executives

Coleman N. Lannum - Vice President of Investor Relations

Jose E. Almeida - Chairman of the Board, Chief Executive Officer and President

Charles J. Dockendorff - Chief Financial Officer and Executive Vice President

Analysts

Robert A. Hopkins - BofA Merrill Lynch, Research Division

David R. Lewis - Morgan Stanley, Research Division

Michael N. Weinstein - JP Morgan Chase & Co, Research Division

Joanne K. Wuensch - BMO Capital Markets U.S.

Frederick A. Wise - Leerink Swann LLC, Research Division

Kristen M. Stewart - Deutsche Bank AG, Research Division

Anthony Petrone - Jefferies & Company, Inc., Research Division

Matthew J. Dodds - Citigroup Inc, Research Division

David H. Roman - Goldman Sachs Group Inc., Research Division

Adam T. Feinstein - Barclays Capital, Research Division

Thomas J. Gunderson - Piper Jaffray Companies, Research Division

Lawrence S. Keusch - Raymond James & Associates, Inc., Research Division

Glenn J. Novarro - RBC Capital Markets, LLC, Research Division

Jason Wittes - Caris & Company, Inc., Research Division

Michael Matson - Mizuho Securities USA Inc., Research Division

Jonathan J. Palmer - Credit Agricole Securities (USA) Inc., Research Division

Presentation

Operator

Good day, ladies and gentlemen, and welcome to the Q2 2012 Covidien plc Earnings Conference Call. My name is Brent, and I will be your operator for today. [Operator Instructions] As reminder, this call is being recorded for replay purposes. I would now like to hand the call over to Cole Lannum, Vice President of Investor Relations. Please proceed.

Coleman N. Lannum

Thanks, Brent, and good morning, everyone. With me today are Joe Almeida, Covidien's Chairman, President and CEO; and Chuck Dockendorff, our Chief Financial Officer.

If you liked this article you might like

Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace

Mallinckrodt Buys Ikaria in $2.3 Billion Hospital Treatment Deal

Stryker and Smith & Nephew Are the Stars to Watch in Medtech's 2015 Merger Dance

Medtronic Avoids U.S. Taxes While Saddling Shareholders With a Hefty Tax Bill

Trim Positions in Stryker Ahead of Fourth-Quarter Earnings; Buy on Pullback